Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors Meeting Abstract
| Authors: | Infante, J. R.; Janku, F.; Tolcher, A. W.; Patel, M. R.; Sullivan, R. J.; Flaherty, K.; Carvajal, R. D.; Varghese, A. M.; Wong, D. J. L.; Sznol, M.; Sosman, J. A.; Wang-Gillam, A.; Burris, H. A.; Ribas, A.; Patel, S. P.; Welsch, D. J.; Saha, S. |
| Abstract Title: | Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036900539 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.2506 |
| Notes: | Meeting Abstract: 2506 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
